Novartis: encouraging data in midgut neuroendocrine tumors
(CercleFinance.com) - Data issued demonstrates that treatment with Novartis' Lutathera provides a significantly longer time to deterioration of quality of life for patients with progressive midgut neuroendocrine tumors, the Swiss drugmaker said on Friday.
Phase III results published in the Journal of Clinical Oncology show that patients reported prolonged maintenance of global health status (overall health indicators such as fatigue, pain, diarrhea) when treated with the drug, Novartis said.
The pharma giant said that the results in a patient population with "limited" therapeutic options were "encouraging".
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Phase III results published in the Journal of Clinical Oncology show that patients reported prolonged maintenance of global health status (overall health indicators such as fatigue, pain, diarrhea) when treated with the drug, Novartis said.
The pharma giant said that the results in a patient population with "limited" therapeutic options were "encouraging".
Copyright (c) 2018 CercleFinance.com. All rights reserved.